These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 16797970)
1. Signalling and survival pathways in multiple myeloma. Bommert K; Bargou RC; Stühmer T Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970 [TBL] [Abstract][Full Text] [Related]
2. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Barillé S; Bataille R; Amiot M Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296 [TBL] [Abstract][Full Text] [Related]
3. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Gadó K; Domján G; Hegyesi H; Falus A Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159 [TBL] [Abstract][Full Text] [Related]
6. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Mitsiades CS; Mitsiades NS; Munshi NC; Richardson PG; Anderson KC Eur J Cancer; 2006 Jul; 42(11):1564-73. PubMed ID: 16765041 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Treon SP; Anderson KC Curr Opin Hematol; 1998 Jan; 5(1):42-8. PubMed ID: 9515202 [TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Hideshima T; Anderson KC Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731 [TBL] [Abstract][Full Text] [Related]
9. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670 [TBL] [Abstract][Full Text] [Related]
10. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641 [TBL] [Abstract][Full Text] [Related]
11. Pathogenesis and management of myeloma bone disease. Christoulas D; Terpos E; Dimopoulos MA Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944 [TBL] [Abstract][Full Text] [Related]
13. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Li QF; Wu CT; Duan HF; Sun HY; Wang H; Lu ZZ; Zhang QW; Liu HJ; Wang LS Br J Haematol; 2007 Sep; 138(5):632-9. PubMed ID: 17686057 [TBL] [Abstract][Full Text] [Related]
14. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Khong T; Sharkey J; Spencer A Haematologica; 2008 Jun; 93(6):860-9. PubMed ID: 18443271 [TBL] [Abstract][Full Text] [Related]
15. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997 [TBL] [Abstract][Full Text] [Related]
18. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Podar K; Richardson PG; Chauhan D; Anderson KC Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175 [TBL] [Abstract][Full Text] [Related]
19. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088 [TBL] [Abstract][Full Text] [Related]
20. Cytokines and signal transduction. Hideshima T; Podar K; Chauhan D; Anderson KC Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]